COMP001
80 evidence topics · 28 sources
Objective
Protocol objectives: dose selection and superiority over 1 mg
Company statement of the trial objective
Role in the new drug application
Location and study date
Study dates and identifiers
| Item | Registry record |
|---|---|
| Other study ID | “COMP001” |
| Study start (actual) | “2019-03-01” |
| Primary completion (actual) | “2021-07-30” |
| Study completion (actual) | “2021-09-27” |
| Results first posted | “2023-04-24” |
Sites: registry record
Study design
Randomized, double-blind, dose-controlled design
“In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Registered design details
| Item | Registry record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Protocol design and visit schedule
Preparation, administration, and follow-up sessions
Screening period and antidepressant taper
Eligibility criteria
Registered eligibility criteria
| Item | Registry record |
|---|---|
| Inclusion | “Diagnosis of TRD” |
| Exclusion | “Other comorbidities” |
| Ages eligible | “18 Years and older” |
| Healthy volunteers | “No” |
Company definition of treatment-resistant depression
Inclusion criteria: protocol
Exclusion criteria: protocol
Treatment
Investigational product by arm
Administration session
Psychological support model
“which randomized 233 adults with TRD in 1:1:1 ratio to a single fixed-dose (25 mg, 10 mg, or 1 mg) of COMP360 that was administered with a well-defined psychological support model that emphasizes safety and self-directed enquiry” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As part of the COMP360 treatment, psychological support was provided to ensure the participants’ physical and psychological safety and consisted of three phases: preparation, administration, and integration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressant washout before and after dosing
Rescue medication
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint definition
“The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company rationale for the scale
Independent remote blinded rating
Scale construction and sensitivity to change
“The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory acceptance as a primary endpoint
Timing of the primary endpoint for a rapid-acting treatment
Clinically meaningful change in treatment-resistant depression
“Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal important difference estimates
“For both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II), MID estimates range between 3 and 9 points, with estimates of 3-6 points likely being the most accurate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission thresholds
“Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint hierarchy and multiplicity control
Time-to-event secondary endpoints in the protocol
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment and power
Actual enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Actual | “233” |
Description of analysis sets
Analysis set definitions
Primary and secondary estimands
Analysis populations reported in the registry
Results
Participant disposition
Completion and withdrawals: company statement
Baseline characteristics
Demographics: registry results
Prior psilocybin experience
Baseline suicidality
Efficacy results
Primary endpoint: change in MADRS total score at Week 3
“Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: company statement
Observed MADRS change at Week 3: registry results
| Analysis set | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Full analysis set, mean (SD) | “-12(12.98)” | “-8.9(10.94)” | “-6.8(11.10)” |
| Per-protocol set, mean (SD) | “-12(12.98)” | “-8.9(11.11)” | “-6.7(11.18)” |
Response, remission, and sustained response
“In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: antidepressant discontinuation before dosing
“Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: psychedelic experience and outcome
“The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: therapeutic alliance
“Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of the alliance itself on therapeutic efficacy were either limited or absent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: pretreatment characteristics and the psychedelic experience
“Dose was the strongest and most consistent predictor of the psychedelic experience.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Some pretreatment characteristics contributed weakly to subjective experiences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory analysis: language-based prediction of response
“Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12. Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Patient-reported measures assessed
Week 3 patient-reported outcomes
“At Week 3, psilocybin 25 mg, compared with 1 mg, was associated with greater improvements from Baseline total scores in all measures. The 10 mg dose produced smaller effects across these measures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory endpoints and multiplicity
Safety results
Severity and timing of treatment-emergent adverse events
Serious adverse events through Week 12: registry results
| Event | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Any serious adverse event | “5/79 (6.33%)” | “6/75 (8.00%)” | “1/79 (1.27%)” |
| Suicidal behaviour | “3/79 (3.80%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Intentional self-injury | “2/79 (2.53%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Suicidal ideation | “2/79 (2.53%)” | “2/75 (2.67%)” | “0/79 (0.00%)” |
| Drug withdrawal syndrome | “1/79 (1.27%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Depression | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| Hospitalisation | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| All-cause mortality | “0/79 (0.00%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
Serious adverse events: company statement
Other adverse events with frequency of 5% or more: registry results
| Event | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Any other adverse event | “60/79 (75.95%)” | “51/75 (68.00%)” | “50/79 (63.29%)” |
| Headache | “27/79 (34.18%)” | “16/75 (21.33%)” | “20/79 (25.32%)” |
| Nausea | “18/79 (22.78%)” | “7/75 (9.33%)” | “4/79 (5.06%)” |
| Fatigue | “12/79 (15.19%)” | “5/75 (6.67%)” | “7/79 (8.86%)” |
| Insomnia | “8/79 (10.13%)” | “11/75 (14.67%)” | “14/79 (17.72%)” |
| Anxiety | “7/79 (8.86%)” | “13/75 (17.33%)” | “3/79 (3.80%)” |
| Mood altered | “7/79 (8.86%)” | “3/75 (4.00%)” | “1/79 (1.27%)” |
| Dizziness | “6/79 (7.59%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Back pain | “6/79 (7.59%)” | “0/75 (0.00%)” | “3/79 (3.80%)” |
| Suicidal ideation | “5/79 (6.33%)” | “3/75 (4.00%)” | “4/79 (5.06%)” |
| Myalgia | “5/79 (6.33%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Panic reaction | “4/79 (5.06%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Euphoric mood | “4/79 (5.06%)” | “5/75 (6.67%)” | “4/79 (5.06%)” |
| Thinking abnormal | “0/79 (0.00%)” | “4/75 (5.33%)” | “0/79 (0.00%)” |
Timing of suicidality events and dose-related events
Study limitations
Summary: functional unblinding, low-dose comparator without an active treatment, antidepressant washout, Week 3 primary endpoint
The authors state that interpretation is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose, and that larger and longer trials, including comparison with existing treatments, are required. Published correspondence disputed the description of the trial as double-blind. The primary endpoint was at Week 3, and the authors state that in the 25 mg group, sustained response at 12 weeks was not generally supportive of the primary results. Participants tapered antidepressants at least two weeks before baseline and were asked to remain off them for at least 3 weeks after dosing; a commentary notes that many started other antidepressants after Week 3. The same commentary notes emergent suicidal ideation and behavior in the 25 mg and 10 mg groups and not in the 1 mg group, and the publication reports suicidal ideation or behavior or self-injury in all dose groups.
Authors' stated limitations: comparator and trial size
Authors' stated limitations: secondary analyses
Functional unblinding: published correspondence
Functional unblinding and expectancy in psychedelic trials
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commentary: dose selection, psychedelic effects, and suicidality
“The findings support use of drug plasma levels to optimize psilocybin doses and to analyze dose-dependent variance in clinical response, instead of using oral dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most side effects (nausea, headache) were comparable between the 10 mg and 25 mg dose groups, but surprisingly, the paper is silent about psychedelic effects even though it reports such effects lasted about 6 h after taking psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, suicidal ideation and behavior history were comparable in all three dose groups prior to the study, but emergent suicidal ideation and behavior was observed in the 25 mg and 10 mg groups and not in the 1 mg group (employed as an active comparator instead of a placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commentary: antidepressant restart after Week 3
“Individuals who participated in the study were asked to stay off other psychotropic medications for the first 3 weeks and most complied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 25 mg dose showed efficacy compared with 1 mg daily at 3 weeks, and this continued until 12 weeks, even though many patients started other antidepressants after week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressant washout before dosing
“It has been suggested that the recent use and discontinuation of antidepressant drugs compromises the action of psilocybin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As evidence is only available from small or uncontrolled samples, this post hoc analysis investigated this using data from the largest, phase II, randomized controlled trial of psilocybin treatment to date.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commentary on the therapeutic alliance analysis
“While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in addition, shaped by methodological decisions that obscure relevant effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, we highlight unexplained deviations from the study protocol that warrant scrutiny.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote